Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury Oct 11, 2022 | ASX News, Incannex Healthcare (ASX:IHL)
Incannex expands IHL-675A indications to include COPD, asthma, bronchitis, and other inflammatory lung conditions – after receiving positive results from additional in vivo studies Feb 4, 2021 | ASX News, Incannex Healthcare (ASX:IHL)